Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment

恩扎鲁胺 前列腺癌 癌症研究 免疫系统 肿瘤微环境 雄激素受体 医学 T细胞 癌症 免疫学 内科学
作者
Pengfei Xu,Joy C. Yang,Bo Chen,Christopher Nip,Jonathan E Van Dyke,Xiong Zhang,Hongwu Chen,Christopher P. Evans,William J. Murphy,Chengfei Liu
出处
期刊:Journal for ImmunoTherapy of Cancer [BMJ]
卷期号:11 (5): e006581-e006581 被引量:53
标识
DOI:10.1136/jitc-2022-006581
摘要

Background Emerging data suggest that patients with enzalutamide-treated prostate cancer with increased programmed death-ligand 1 (PD-L1) expression may benefit from anti-PD-L1 treatment. Unfortunately, the Phase III IMbassador250 clinical trial revealed that the combination of atezolizumab (a PD-L1 inhibitor) and enzalutamide failed to extend overall survival in patients with castration-resistant prostate cancer (CRPC). However, the mechanisms underlying treatment failure remain unknown. Methods Human CRPC C4-2B cells and murine Myc-CaP cells were chronically exposed to increasing concentrations of enzalutamide and the cells resistant to enzalutamide were referred to as C4-2B MDVR and Myc-CaP MDVR, respectively. The mechanisms of action in drug-resistant prostate cancer cells were determined using RNA sequencing analyses, RNA interference, real-time PCR, western blotting, and co-culturing technologies. Myc-CaP and Myc-CaP MDVR tumors were established in syngeneic FVB mice, and tumor-infiltrating leukocytes were isolated after enzalutamide treatment. The stained immune cells were determined by flow cytometry, and the data were analyzed using FlowJo. Results Immune-related signaling pathways (interferon alpha/gamma response, inflammatory response, and cell chemotaxis) were suppressed in human enzalutamide-resistant prostate cancer cells. PD-L1 was overexpressed and negatively regulated by androgen receptor signaling in resistant cells and patient with CRPC cohorts. Enzalutamide treatment decreased CD8 + T-cell numbers but increased monocytic myeloid-derived suppressor cell (M-MDSC) populations and PD-L1 expression within murine Myc-CaP tumors. Similarly, chemotaxis and immune response-regulating signaling pathways were suppressed, and PD-L1 expression was also increased using enzalutamide-resistant Myc-CaP MDVR cells. Notably, MDSC populations were significantly increased in Myc-CaP MDVR orthotopic tumors compared with those in Myc-CaP parental tumors. Co-culturing bone marrow cells with Myc-CaP MDVR cells significantly promoted MDSC differentiation and shifted towards M2 macrophage skewing. Conclusions Our study suggests that immunosuppressive signaling can be promoted directly by enzalutamide-resistant prostate cancer cells and may be a potential means by which the efficacy of immune checkpoint inhibitors in enzalutamide-resistant prostate cancer is diminished.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
浮尘完成签到,获得积分10
刚刚
yht完成签到,获得积分10
刚刚
王王完成签到,获得积分10
1秒前
自由的盼波完成签到 ,获得积分10
1秒前
nanke发布了新的文献求助10
1秒前
钟鱼完成签到,获得积分10
1秒前
乐空思的应助被FF采纳,获得30
2秒前
2秒前
2秒前
斯文败类的应助被旧人旧街采纳,获得10
3秒前
我居然要写两篇小论文完成签到 ,获得积分10
3秒前
今者当歌完成签到,获得积分10
3秒前
梦想家完成签到,获得积分10
3秒前
小茗同学完成签到 ,获得积分10
3秒前
3秒前
4秒前
4秒前
ru发布了新的文献求助30
4秒前
4秒前
背后的语海完成签到 ,获得积分10
4秒前
于小野发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
沙克几十块完成签到,获得积分10
6秒前
无花果的应助被史萌采纳,获得10
6秒前
Ava的应助被uiiii采纳,获得10
6秒前
6秒前
7秒前
钱璐璐完成签到,获得积分10
7秒前
nihao发布了新的文献求助10
8秒前
乐观无心完成签到,获得积分10
8秒前
上官若男的应助被铝合金男孩采纳,获得10
8秒前
8秒前
8秒前
似风完成签到,获得积分10
8秒前
zgnh完成签到,获得积分10
8秒前
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315